COVID-19 Information

Edit Entry | Edit CV

Paul M. Guyre, PhD

Title(s):
Emeritus Professor of Microbiology and Immunology

Additional Titles/Positions/Affiliations:
VP for Research and Discovery
Celdara Medical, LLC

Department(s):
Microbiology and Immunology

Education:
Montclair State College, BA 1972
U. New Hampshire, MS 1976
U. New Hampshire, PHD 1979

Programs:
Immunology Program
Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center
Program in Experimental and Molecular Medicine

NIH Biosketch:
Guyre_P_BIO_2020-12-20.pdf

Websites:
https://geiselmed.dartmouth.edu/faculty/facultydb/view.php/?uid=184


Contact Information:

Geisel School of Medicine at Dartmouth
HB 7556
Lebanon NH 03756

Phone: 603 650-7924
Email: paul.guyre@dartmouth.edu


Professional Interests:

Dr. Guyre's principal research interests to date have been: (i) Cancer immunotherapy; (ii) understanding the regulation and function of IgG Fc receptors on phagocytes, and (iii) how hormones and cytokines regulate the functional activity of white blood cells including monocytes, macrophages, dendritic cells, and neutrophils. The Guyre lab team is currently focused on (i) inflammatory mechanisms induced by COVID-19 antibodies, (ii) finding biomarkers for the neuroimmune related disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and (iii) the tick-induced mammalian meat allergy Alpha Gal Syndrome. Vastly underdiagnosed, IgE anti-alpha gal (a sugar found on all mammals except humans) can induce life threatening anaphylaxis to not only meals of beef and pork, but to medications containing gelatin or lactose.

Courses Taught:

DMSI Physiology
DMSI Immunology
Advanced Endocrinology
Advanced Biomedical Sciences

Biography:

After Dr. Guyre received his Ph.D from the University of New Hampshire in 1978, he trained as a postodoctoral research associate with Allan Munck in the DMS Department of Physiology. He joined the Physiology faculty in 1980, and has been a Professor of Physiology and of Microbiology/Immunology since 1991.


Selected Publications:

 

  • Yeager MP, Guyre CA, Sites BD, Collins JE, Pioli PA, Guyre PM The Stress Hormone Cortisol Enhances Interferon-gamma-Mediated Proinflammatory Responses of Human Immune Cells. Anesth Analg. 2018 Aug;127(2):556-563. doi: 10.1213/ANE.0000000000003481 (view details in PubMed)

  • Yeager MP, Rassias AJ, Pioli PA, Beach ML, Wardwell K, Collins JE, Lee HK, Guyre PM. Pretreatment with stress cortisol enhances the human systemic inflammatory response to bacterial endotoxin. Crit Care Med. 2009 Oct;37(10):2727-32. doi: 10.1097/ccm.0b013e3181a592b3. (view details in PubMed)

  • Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, Guyre PM. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol. 2006 Jul;80(1):26-35. doi: 10.1189/jlb.1205756 (view details in PubMed)

  • Sulahian TH, Pioli PA, Wardwell K, Guyre PM. Cross-linking of FcgammaR triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163. J Leukoc Biol. 2004 Jul;76(1):271-7. doi: 10.1189/jlb.1003523. (view details in PubMed)

  • Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods. 2001 Feb 1;248(1-2):149-65. doi: 10.1016/s0022-1759(00)00355-0. (view details in PubMed)

  • Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM, Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother. J Immunother. 2001 Jan- Feb;24(1):79-87. doi: 10.1097/00002371-200101000-00009 (view details in PubMed)

  • Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol. 1995 Sep;13(9):2281-92. doi: 10.1200/JCO.1995.13.9.2281 (view details in PubMed)

  • Fanger MW, Morganelli PM, Guyre PM. Use of bispecific antibodies in the therapy of tumors. Curr Opin Immunol. 1993 Feb;5(1):108-13. doi: 10.1016/0952-7915(93)90089-b (view details in PubMed)

  • Anderson CL, Guyre PM, Whitin JC, Ryan DH, Looney RJ, Fanger MW. Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes. Antibody characterization and induction of superoxide production in a monocyte cell line. J Biol Chem. 1986 Sep 25;261(27):12856-64. (view details in PubMed)

  • Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest. 1983 Jul;72(1):393-7. doi: 10.1172/jci110980 (view details in PubMed)